A T<inf>2</inf>S cross-reactive material (compound W) in hyperthyroid patients with trophoblastic disease

• Main Authors: R. Rajatanavin, D. A. Fisher, L. Chailurkit, W. S. Huang, S. Srisupandit, S. Y. Wu
• Other Authors: Mahidol University
• Format: Article
• Published: 2018
• Subjects: Biochemistry, Genetics and Molecular Biology; Medicine
• Online Access: https://repository.li.mahidol.ac.th/handle/123456789/25369

In a previous study we observed increased serum levels of a 3,3'- diiodothyronine sulfate (T2S)-like material (compound W) in women who received human chorionic gonadotropin (hCG) treatment. In the present study we assessed serum compound W values in 113 women (total serum sample: 190) with trophoblastic disease, in 7 normal nonpregnant women during the menstrual cycle and 7 women given hCG treatment in the course of in vitro fertilization. Fifty-three women with trophoblastic disease had serum free thyroxine (FT4) concentrations greater than 3.0 ng/dL with suppressed serum thyrotropin (TSH) levels; 61 had FT4values less than 3.0 ng/dL with a mean TSH of 0.83 mU/L. Mean (± SE) compound W concentrations in the high FT4group were significantly higher than in the low FT4group (76 ± 8.1 vs. 21 ± 1.7 ng T2S equivalent, p < 0.001). There were significant correlations between serum hCG and compound W concentrations (r = 0.472, p < 0.001), serum FT4and hCG (r = 0.503, p < 0.0001) and serum FT4and compound W (r = 0.585, p < 0.0001). In nonpregnant women serum compound W levels increased from 7.5 ± 8 ng/dL at the end of the menstrual period to 15 ± 1.7 ng/dL 21 days after the last menstrual period. Finally, a single dose of hCG (10,000 USP units, intramuscularly) increased mean (± SE) serum compound W levels from 12.8 ± 2.3 to 64 ± 9.7 ng/dL and 54 ± 12 ng/dL at 9 and 16 days, respectively. These results indicate that hCG and perhaps luteinizing hormone (LH) increase serum compound W concentrations in women. The mechanism and significance presently are unclear.